Salmonella species cause disease or death in millions of individuals every year who ingest contaminated food or water. Individuals who survive Salmonella infection develop robust immunity that is dependent on antibodies that facilitate bacterial phagocytosis by macrophages, and lymphokines from CD4+ T cells that stimulate macrophages to kill engulfed bacteria. For practical reasons, a subunit vaccine capable of inducing the level of immunity that can be induced by live organisms, is desirable. Unfortunately, immunization with individual Salmonella proteins usually induces only partial immunity. The long-term goal of this project is to overcome this inefficiency and produce an effective subunit vaccine for Salmonella. Our hypothesis is that individual Salmonella proteins are less protective than attenuated organisms because of a lack of presentation at all times during infection, inherently weak adjuvant activity, and poor entry into the mucosal lymphoid organs.
Our specific aim i s to produce a single vaccine that addresses each of these weaknesses. We propose to identify immunodominant peptides from S. typhimurium proteins that activate CD4+ T cells early and late after S. typhimurium infection. These peptides will be incorporated into particles along with the Toll-like receptor 5-binding portion of S. typhimurium FliC, which functions as an adjuvant and contains B cell epitopes, and the beta 1 integrin-binding domain of Yersinia pseudotuberculosis, which facilitates M cell translocation of particles into the Peyer's patches. The particles containing all of these components will be tested for the ability to generate protective immunity to Salmonella, and novel methods to track peptide:MHC II complexes, specific CD4+ T cells, and antibodies will be employed to assess the cellular mechanisms responsible for immunity. Completion of these aims will provide a framework for the rational design of effective subunit vaccines for Salmonella, other infectious agents, and cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI066018-05
Application #
7808016
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Alexander, William A
Project Start
2005-09-01
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
5
Fiscal Year
2010
Total Cost
$317,211
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Tubo, Noah J; Pagán, Antonio J; Taylor, Justin J et al. (2013) Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection. Cell 153:785-96
Nelson, Ryan W; McLachlan, James B; Kurtz, Jonathan R et al. (2013) CD4+ T cell persistence and function after infection are maintained by low-level peptide:MHC class II presentation. J Immunol 190:2828-34
Pepper, Marion; Pagán, Antonio J; Igyártó, Botond Z et al. (2011) Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity 35:583-95
Moon, James J; Chu, H Hamlet; Hataye, Jason et al. (2009) Tracking epitope-specific T cells. Nat Protoc 4:565-81
McLachlan, James B; Catron, Drew M; Moon, James J et al. (2009) Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 30:277-88